Stem cell therapy has clinical value for prostate cancer
- Subversive discovery: Can lymph nodes promote the success of cancer immunotherapy?
- Major Discovery: Cancer cell PD-L1 does not inhibit T cell toxicity
- The new coronavirus may kill cancer cells and achieve a permanent cure!
- Why did the Alzheimer’s drug candidate BACE1 inhibitor fail?
- LRTI Death: Research spanning 80 years confirms for the first time
- The decline of the global antibiotic market is threatening the development of new drugs
Stem cell therapy has clinical value for prostate cancer
- More than 1 million Chinese died after China quit “Zero-COVID policy”?
- Why is Vinyl chloride listed as a Class A “known human carcinogen” ?
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
Stem cell therapy has clinical value for prostate cancer. Stem cell injection for treatment of urinary incontinence after radical prostatectomy.
In recent years, with the rapid development of stem cell technology, its powerful advantages in high-speed proliferation, low immunogenicity, multidirectional differentiation, immunosuppression, and tissue repair have been widely used.
Because stem cells have the unique characteristics of immunosuppression, anti-inflammatory, anti-fibrosis and promoting angiogenesis, especially in inhibiting the occurrence and development of inflammation, it provides a new method for the intervention of male prostate cancer.
Traditional methods of intervention in prostate cancer have certain limitations
In recent years, the incidence of prostate cancer has gradually increased, and it has become the most common malignant tumor in men. As the main treatment for radical prostatectomy, complications such as urinary incontinence often occur after surgery, which seriously affects the quality of life of patients.
Based on the severity of postoperative urinary incontinence and the patient’s independent choice, there are now a variety of treatment methods, including drug therapy, surgical intervention (various types of mid-urethral suspension, filler therapy), and cell therapy.
All these treatment methods have certain limitations, so stem cell transplantation, as an alternative treatment method, has become a recent research focus.
Regeneration and repair of stem cells on urethral tissue
A number of studies have confirmed that the neurally differentiated adipose stem cells can exhibit good glial properties and participate in nerve regeneration.
Injection of adipose stem cells around the urethra can not only increase the resistance of the urethra, but these adipose stem cells can differentiate into smooth muscle cells and increase the contractility of the urethra.
Clinical Study
Purpose
The preliminary clinical experience of transurethral injection of autologous adipose-derived stem cells in the treatment of urinary incontinence after radical prostatectomy was summarized, and its safety and efficacy were evaluated.
Method
The scientific research team performed stem cell transplantation on 6 patients with complications of urinary incontinence after radical prostatectomy.
Under general anesthesia, liposuction was used to obtain 50 mL of autologous adipose tissue, and after cell processing by Celution (developed by Cytori Therapeutics) system, autologous adipose stem cells were obtained.
The autologous adipose stem cell suspension and the corresponding mixture were injected into the submucosal area of the urethral membrane under the guidance of a cystoscope.
Within 12 weeks after cell therapy, a 24-hour urine pad test, urinary incontinence quality questionnaire, urodynamics, and MRI were used to assess the structural and functional changes of the external urethral sphincter.
Results
The 24-hour urinary pad test, the International Incontinence Questionnaire (ICIQ-SF) score, the maximum urethral closure pressure and the functional urethral length were all significantly improved in the 12th week after treatment.
The average maximum urethral closure pressure was 4.312 from the pre-treatment The kPa rose to 6.223 kPa (12 weeks), and the length of the functional urethra increased from 6.1 mm to 8.3 mm (12 weeks). See table 1
Summary
Injection of autologous adipose stem cells through the urethra is a safe and feasible method to treat urinary incontinence after radical prostatectomy.
This new treatment method is simple, minimally invasive and highly effective.
However, larger-scale multicenter randomized controlled trials and long-term follow-up are still needed to further evaluate its effectiveness and safety.
Stem cell therapy has clinical value for prostate cancer
(source:internet, reference only)
Disclaimer of medicaltrend.org
